A Phase I/II study of AZD4512 monotherapy or in combination with anticancer agents in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Trial Identifier: D9890C00001
Sponsor: AstraZeneca
Start Date: September 2025
Primary Completion Date: March 2028
Study Completion Date: March 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
CN Chengdu, CN, 610041
CN Guangzhou, CN, 510060
GB London, GB, W1T 7HA
GB Newcastle-Upon-Tyne, GB, NE7 7DN
IT Bologna, IT, 40138
IT Milano, IT, 20141
IT Milano, IT, 20133
JP Bunkyo-ku, JP, 113-8677
JP Koto-ku, JP, 135-8550
KR Seoul, KR, 03080
KR Seoul, KR, 5505
TW Taichung, TW, 40705
TW Taipei City, TW, 106
US, CA Irvine, CA, US, 92618
US, FL Jacksonville, FL, US, 32224
US, MN Rochester, MN, US, 55905
US, NY New York, NY, US, 10021
US, NY New York, NY, US, 10016
US, TN Franklin, TN, US, 37067